European Medicines Agency approves encorafenib in combination with cetuximab for treatment of adults with BRAFV600E-mutant metastatic colorectal cancer

This is the first regimen licensed in Europe for the treatment of this specific patient population. Approval was based on the Phase III BEACON CRC trial which showed an improvement in overall survival (9.3 v 5.9 months with control [cetuximab plus irinotecan]; no p value stated).